Navigation Links
Lorus Therapeutics Reports Fourth Quarter Results for Fiscal Year 2008
Date:7/21/2008

$10.2 million in operating activities in the year ended May 31, 2008 compared with $6.3 million during the year ended May 31, 2007 reflecting the increase in research and development activities during the year. At May 31, 2008, Lorus had cash and cash equivalents, short-term investments and marketable securities of $9.4 million compared to $12.2 million at May 31, 2007. Lorus believes that its current cash and cash equivalents, short-term investments and marketable securities and interest income will be sufficient to carry out the current research and development plans and operations through to the first quarter of fiscal 2010.

Lorus Therapeutics Inc.

Consolidated Statements of Loss

Years Ended May 31

-------------------------------------

(Canadian dollars) 2008 2007 2006

-------------------------------------------------------------------------

REVENUE $ 133 $ 107 $ 26

-------------------------------------------------------------------------

EXPENSES

Cost of sales 2 16 3

Research and development 6,087 3,384 10,237

General and administrative 3,888 3,848 4,334

Stock-based compensation 719 503 1,205

Depreciation and amortization of

fixed assets 317 402 771

-------------------------------------------------------------------------

Operating expenses 11,013 8,153 16,550

Interest expense on convertible

debentures 1,029 1,050 882

Accretion in carrying value of

convertible debentures 1,045
'/>"/>

SOURCE Lorus Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Lorus Therapeutics Receives $600 Thousand From Escrow Account
2. Lorus Therapeutics Provides an Update on Progress in Virulizin(R) Development Program
3. Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML)
4. Lorus Therapeutics Strengthens Its Senior Management Team Through Internal Promotions
5. Lorus initiates development program exploring novel route of administration for LOR-2040
6. Lorus Therapeutics presents new findings for the anticancer drugs LOR-253 and LOR-2040
7. Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R)
8. Lorus Therapeutics Appoints Peter Korth as Chief Financial Officer
9. Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
10. Zenobia Therapeutics, Inc. Begins Operations as a Fragment-Based Lead Discovery Company
11. Northwest Biotherapeutics to Present at Next Generation Vaccine Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Dec. 18, 2014 Egenix, Inc. is pleased to ... Chairman of the Board, to succeed Donald Fresne ; ... will continue as a member of the Board.  In recognition ... to the company over almost twenty years, the Board designated ... of Directors has established a Search Committee to find a ...
(Date:12/17/2014)... USA (PRWEB) December 16, 2014 ... manager at Philipps- Universität Marburg’s Department of Physics, ... photonics, in the newly released SPIE Women ... never be too shy to ask questions.” , ... technology, engineering, and mathematics) occupations ranging from university ...
(Date:12/17/2014)... IN (PRWEB) December 17, 2014 ... Laboratory Excellence following its most recent COLA inspection. ... by COLA, a national healthcare accreditation organization. Accreditation ... standards of quality in day-to-day operations, demonstrate continued ... pass a rigorous on-site laboratory survey. ...
(Date:12/17/2014)... , Dec. 17, 2014 CASI Pharmaceuticals, Inc. ... to the acquisition, development and commercialization of innovative therapeutics ... global market with a primary commercial focus on ... been granted a Type C meeting with the U.S. ... will be held in February 2015.  During this meeting ...
Breaking Biology Technology:Network, Multitask, Persevere: SPIE Women in Optics Planner Subjects Share from Experience 2Network, Multitask, Persevere: SPIE Women in Optics Planner Subjects Share from Experience 3Xeno Diagnostics Receives 3rd Award for Laboratory Excellence 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5
... we didnt spend so much time trying to be the next ... Wisconsins technology roadmap is to become a Midwest carbon copy of ... differences in business, labor and general population are so vast that ... and still not come close. If its true that the ...
... , WTN: What's the next big thing in technology? E-commence? ... will be the continuous improvements in CRM tools and software. ... better connecting customers with companies and institutions. All of ... element that surrounds our customers. Doing so will result ...
... about weblogs - until now. Truth be told - and probably ... bandwagons. If everyone is going right, I'll move left just to ... on blogging was that it was just another technology-enabled fad. Any ... other fool could read it. Of course, there was, initially, a ...
Cached Biology Technology:What If We Cut Our Own Path? 2What If We Cut Our Own Path? 3The Next Big Thing in E-Commerce - Guild.com CEO comments on Wisconsin's technology vision 2The Blog Nation 2The Blog Nation 3
(Date:12/17/2014)... YORK , Dec. 15, 2014  HITLAB ... Good Clinical Practices (GCP) audit to confirm its ... (FDA) regulations. This accomplishment enables HITLAB to conduct ... utilizing the highest principles for patient safety and ... improve global healthcare access, quality, and delivery with ...
(Date:12/17/2014)... 16, 2014 Research and Markets ... the "Global Chemical Sensor Market 2015-2019" ... http://photos.prnewswire.com/prnh/20130307/600769 One major trend ... for medical sensors in biomedical applications. Chemical sensors ... and correct diagnosis during surgical procedures. The Global ...
(Date:12/15/2014)... 12, 2014 Research and Markets ... the "Global Facial Recognition Market 2015-2019" ... http://photos.prnewswire.com/prnh/20130307/600769 Facial recognition is ... Facial recognition system measures the overall facial feature ... mouth, and the distance between eyes. Facial recognition ...
Breaking Biology News(10 mins):HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
... the coralline algae fossils that lived on the last coral ... years ago. Mediterranean algae and coral reefs began to resemble ... the Indian Ocean and global cooling 15 and 20 million ... University of Granada (UGR) and the University of Modena and ...
... A study comparing how two common dietary oil ... themselves, can lower body fat in obese postmenopausal women ... were safflower oil, a common cooking oil, and conjugated ... meat and dairy products that has been associated with ...
... Antonio Medical mycologists in The South Texas Center ... Biology at The University of Texas at San Antonio ... Valley Fever, a respiratory infection of humans, commonly called ... fungus. For the first time, the researchers ...
Cached Biology News:Coralline algae in the Mediterranean lost their tropical element between 5 and 7 million years ago 2Two dietary oils, two sets of benefits for older women with diabetes 2Two dietary oils, two sets of benefits for older women with diabetes 3Two dietary oils, two sets of benefits for older women with diabetes 4UTSA infectious disease researchers advancing vaccine against Valley fever 2
... B-Bridge's siSolutions RNAi Services offer you ... your siRNA studies. B-Bridges advanced design ... technical expertise ensure that you obtain ... siSolutions siRNA Design Service utilizes their ...
... To score SNPs, Polymorphic uses proven, ... standard in DNA analysis. We use high ... can be confirmed by sequencing in both ... provides sequence context information, further confirming the ...
... The Sub-Cell Model 96 and PowerPac basic ... electrophoresis of nucleic acids in agarose gels. This ... 25 x 10 cm UV-transparent gel tray with ... basic power supply, 100-120 and 220-240 V, provides ...
... cell and PowerPac basic power supply are used ... in agarose gels. The mini format cell includes ... and leveling bubble. The PowerPac basic power supply, ... V, 4-400 mA, and 75 W. Power cord ...
Biology Products: